Drug delivery specialist SHL Medical opened the doors to its new $220 million autoinjector production facility in South Carolina, further boosting the Swiss company’s global footprint.
The facility, located in north Charleston, will produce autoinjectors that deliver drugs to treat endocrine and metabolic disorders as well as medicines for musculoskeletal diseases and other therapeutic areas, the company said in an April 1 press release.
The 360,000-square-foot plant, which is fully automated, is credited with creating 300 jobs and features the latest in medical device injection molding technology.
“U.S.-based production is a major step forward in our global expansion and reinforces our position as the leader in providing end-to-end drug delivery solutions,” Ulrich Faessler, SHL’s CEO and chairman, said in the release. “With our established site in Taiwan and the upcoming facility in Switzerland, we will be the only autoinjector manufacturer operating across three continents, bringing us even closer to our customers.”
The new production facility, a project first announced in 2022, complements SHL’s current assembly labeling and packaging operations in Deerfield Beach, Florida.
In 2022, SHL garnered financial support for its drug delivery growth plan with the addition of a consortium of investors that included Stockholm-based EQT, ATHOS and other co-investors.
Overall, SHL said it expects to deliver 1.5 billion devices to customers this year.